DiaMedica schedules Oct. 23 webinar to present interim Phase 2 early-onset fetal growth restriction data for DM199
DMAC•DiaMedica Therapeutics scheduled an Oct. 23, 2026, virtual webinar to present safety findings and initial observations from the first Phase 2 cohort of DM199 in early-onset fetal growth restriction. Enrollment in the first cohort is complete, and dosing has started in the second.
1. Webinar and trial update
DiaMedica Therapeutics said it will hold a virtual KOL webinar on Oct. 23, 2026, about DM199 in early-onset fetal growth restriction. The company said early interim topline findings from the first Phase 2 cohort have been generated; enrollment is complete in that cohort, and dosing has started in the second.
